-
Something wrong with this record ?
Classification of current anticancer immunotherapies
L. Galluzzi, E. Vacchelli, JM. Bravo-San Pedro, A. Buqué, L. Senovilla, EE. Baracco, N. Bloy, F. Castoldi, JP. Abastado, P. Agostinis, RN. Apte, F. Aranda, M. Ayyoub, P. Beckhove, JY. Blay, L. Bracci, A. Caignard, C. Castelli, F. Cavallo, E....
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Free Medical Journals
from 2010
Freely Accessible Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
- MeSH
- Immunotherapy methods MeSH
- Humans MeSH
- Neoplasms immunology therapy MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.
Center for Immunotherapy Roswell Park Cancer Institute Buffalo NY USA
Cold Spring Harbor Laboratory Cold Spring Harbor NY USA
Dept of Biochemistry University of Lausanne Epalinges Switzerland
Dept of Clinical Oncology Leiden University Medical Center Leiden The Netherlands
Dept of Hematology Oncology and Molecular Medicine Istituto Superiore di Sanità Rome Italy
Dept of Immuno GeneTherapy Mie University Graduate School of Medicine Tsu Japan
Dept of Microbiology Tumor and Cell Biology Karolinska Institute Stockholm Sweden
Dept of Molecular Medicine and Immunology Mayo Clinic College of Medicine Rochester MN USA
Dept of Neurological Surgery University of California San Francisco San Francisco CA USA
Dept of Oncology Karolinska Institute Hospital Stockholm Sweden
Dept of Pathology The Cancer Research Center The University of Chicago Chicago IL USA
Div of Hematology Oncology Northwestern University Feinberg School of Medicine Chicago IL USA
Donald A Adam Comprehensive Melanoma Research Center Moffitt Cancer Center Tampa FL USA
Equipe 11 Centre Léon Bérard Lyon France
Glaxo Smith Kline Cancer Immunotherapy Consortium Collegeville PA USA
Gustave Roussy Cancer Campus Villejuif France
INSERM U1102 Saint Herblain France Institut de Cancérologie de l'Ouest Saint Herblain France
INSERM U1160 Paris France Groupe Hospitalier Saint Louis Lariboisière F Vidal Paris France
Institute of Medical Immunology Martin Luther University Halle Wittenberg Halle Germany
Institute of Medical Microbiology Immunology and Hygiene Technical University Munich Munich Germany
Instituto de Medicina Molecular Universidade de Lisboa Lisboa Portugal
Istituto Giannina Gaslini Genova Italy
Knight Cancer Institute Oregon Health and Science University Portland OR USA
Laboratorio de Inmunopatología Instituto de Biología y Medicina Experimental Buenos Aires Argentina
Memorial Sloan Kettering Cancer Center New York NY USA
MRC Human Immunology Unit Weatherall Institute of Molecular Medicine University of Oxford Oxford UK
National Cancer Institute Bethesda MD USA
National Center for Cancer Care and Research Hamad Medical Corporation Doha Qatar
National Center for Tumor Diseases University Medical Center Heidelberg Heidelberg Germany
Research Dept of Surgical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA
Sect of Hematology and Immunobiology Yale Cancer Center Yale University New Haven CT USA
The Jackson Laboratory for Genomics Medicine Farmington CT USA
Translational Immunology Division German Cancer Research Center Heidelberg Germany
Unit of Clinical and Experimental Immunology Humanitas Clinical and Research Institute Rozzano Italy
University of Michigan School of Medicine Ann Arbor MI USA
University of Pittsburgh Cancer Institute Laboratory Pittsburgh PA USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000428
- 003
- CZ-PrNML
- 005
- 20160804085632.0
- 007
- ta
- 008
- 160108s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.18632/oncotarget.2998 $2 doi
- 035 __
- $a (PubMed)25537519
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Galluzzi, Lorenzo $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.
- 245 10
- $a Classification of current anticancer immunotherapies / $c L. Galluzzi, E. Vacchelli, JM. Bravo-San Pedro, A. Buqué, L. Senovilla, EE. Baracco, N. Bloy, F. Castoldi, JP. Abastado, P. Agostinis, RN. Apte, F. Aranda, M. Ayyoub, P. Beckhove, JY. Blay, L. Bracci, A. Caignard, C. Castelli, F. Cavallo, E. Celis, V. Cerundolo, A. Clayton, MP. Colombo, L. Coussens, MV. Dhodapkar, AM. Eggermont, DT. Fearon, WH. Fridman, J. Fučíková, DI. Gabrilovich, J. Galon, A. Garg, F. Ghiringhelli, G. Giaccone, E. Gilboa, S. Gnjatic, A. Hoos, A. Hosmalin, D. Jäger, P. Kalinski, K. Kärre, O. Kepp, R. Kiessling, JM. Kirkwood, E. Klein, A. Knuth, CE. Lewis, R. Liblau, MT. Lotze, E. Lugli, JP. Mach, F. Mattei, D. Mavilio, I. Melero, CJ. Melief, EA. Mittendorf, L. Moretta, A. Odunsi, H. Okada, AK. Palucka, ME. Peter, KJ. Pienta, A. Porgador, GC. Prendergast, GA. Rabinovich, NP. Restifo, N. Rizvi, C. Sautès-Fridman, H. Schreiber, B. Seliger, H. Shiku, B. Silva-Santos, MJ. Smyth, DE. Speiser, R. Spisek, PK. Srivastava, JE. Talmadge, E. Tartour, SH. Van Der Burg, BJ. Van Den Eynde, R. Vile, H. Wagner, JS. Weber, TL. Whiteside, JD. Wolchok, L. Zitvogel, W. Zou, G. Kroemer,
- 520 9_
- $a During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a nádory $x imunologie $x terapie $7 D009369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vacchelli, Erika $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France.
- 700 1_
- $a Bravo-San Pedro, José-Manuel $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France.
- 700 1_
- $a Buqué, Aitziber $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France.
- 700 1_
- $a Senovilla, Laura $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France.
- 700 1_
- $a Baracco, Elisa Elena $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
- 700 1_
- $a Bloy, Norma $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
- 700 1_
- $a Castoldi, Francesca $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France. Sotio a.c., Prague, Czech Republic.
- 700 1_
- $a Abastado, Jean-Pierre $u Pole d'innovation thérapeutique en oncologie, Institut de Recherches Internationales Servier, Suresnes, France. $7 gn_A_00000193
- 700 1_
- $a Agostinis, Patrizia $u Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium. $7 gn_A_00002234
- 700 1_
- $a Apte, Ron N $u The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. $7 gn_A_00007885
- 700 1_
- $a Aranda, Fernando $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Group of Immune receptors of the Innate and Adaptive System, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. $7 gn_A_00007978
- 700 1_
- $a Ayyoub, Maha $u INSERM, U1102, Saint Herblain, France. Institut de Cancérologie de l'Ouest, Saint Herblain, France. $7 gn_A_00010635
- 700 1_
- $a Beckhove, Philipp $u Translational Immunology Division, German Cancer Research Center, Heidelberg, Germany.
- 700 1_
- $a Blay, Jean-Yves $u Equipe 11, Centre Léon Bérard (CLR), Lyon, France. Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France.
- 700 1_
- $a Bracci, Laura $u Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
- 700 1_
- $a Caignard, Anne $u INSERM, U1160, Paris, France. Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France.
- 700 1_
- $a Castelli, Chiara $u Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
- 700 1_
- $a Cavallo, Federica $u Molecular Biotechnology Center, Dept. of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
- 700 1_
- $a Celis, Estaban $u Cancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA, USA.
- 700 1_
- $a Cerundolo, Vincenzo $u MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
- 700 1_
- $a Clayton, Aled $u Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK. Velindre Cancer Centre, Cardiff, UK.
- 700 1_
- $a Colombo, Mario P $u Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
- 700 1_
- $a Coussens, Lisa $u Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
- 700 1_
- $a Dhodapkar, Madhav V $u Sect. of Hematology and Immunobiology, Yale Cancer Center, Yale University, New Haven, CT, USA.
- 700 1_
- $a Eggermont, Alexander M $u Gustave Roussy Cancer Campus, Villejuif, France.
- 700 1_
- $a Fearon, Douglas T $u Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
- 700 1_
- $a Fridman, Wolf H $u INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Université Pierre et Marie Curie/Paris VI, Paris, France. Equipe 13, Centre de Recherche des Cordeliers, Paris, France.
- 700 1_
- $a Fučíková, Jitka $u Sotio a.c., Prague, Czech Republic. Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
- 700 1_
- $a Gabrilovich, Dmitry I $u Dept. of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- 700 1_
- $a Galon, Jérôme $u INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Université Pierre et Marie Curie/Paris VI, Paris, France. Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France.
- 700 1_
- $a Garg, Abhishek $u Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium.
- 700 1_
- $a Ghiringhelli, François $u INSERM, UMR866, Dijon, France. Centre Georges François Leclerc, Dijon, France. Université de Bourgogne, Dijon, France.
- 700 1_
- $a Giaccone, Giuseppe $u Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
- 700 1_
- $a Gilboa, Eli $u Dept. of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA.
- 700 1_
- $a Gnjatic, Sacha $u Sect. of Hematology/Oncology, Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- 700 1_
- $a Hoos, Axel $u Glaxo Smith Kline, Cancer Immunotherapy Consortium, Collegeville, PA, USA.
- 700 1_
- $a Hosmalin, Anne $u Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. INSERM, U1016, Paris, France. CNRS, UMR8104, Paris, France. Hôpital Cochin, AP-HP, Paris, France.
- 700 1_
- $a Jäger, Dirk $u National Center for Tumor Diseases, University Medical Center Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Kalinski, Pawel $u Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA. Dept. of Immunology and Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA.
- 700 1_
- $a Kärre, Klas $u Dept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
- 700 1_
- $a Kepp, Oliver $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
- 700 1_
- $a Kiessling, Rolf $u Dept. of Oncology, Karolinska Institute Hospital, Stockholm, Sweden.
- 700 1_
- $a Kirkwood, John M $u University of Pittsburgh Cancer Institute Laboratory, Pittsburgh, PA, USA.
- 700 1_
- $a Klein, Eva $u Dept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
- 700 1_
- $a Knuth, Alexander $u National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
- 700 1_
- $a Lewis, Claire E $u Academic Unit of Inflammation and Tumour Targeting, Dept. of Oncology, University of Sheffield Medical School, Sheffield, UK.
- 700 1_
- $a Liblau, Roland $u INSERM, UMR1043, Toulouse, France. CNRS, UMR5282, Toulouse, France. Laboratoire d'Immunologie, CHU Toulouse, Université Toulouse II, Toulouse, France.
- 700 1_
- $a Lotze, Michael T $u Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA.
- 700 1_
- $a Lugli, Enrico $u Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy.
- 700 1_
- $a Mach, Jean-Pierre $u Dept. of Biochemistry, University of Lausanne, Epalinges, Switzerland.
- 700 1_
- $a Mattei, Fabrizio $u Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
- 700 1_
- $a Mavilio, Domenico $u Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy. Dept. of Medical Biotechnologies and Translational Medicine, University of Milan, Rozzano, Italy.
- 700 1_
- $a Melero, Ignacio $u Dept. of Immunology, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain. Dept. of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
- 700 1_
- $a Melief, Cornelis J $u ISA Therapeutics, Leiden, The Netherlands. Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Mittendorf, Elizabeth A $u Research Dept. of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
- 700 1_
- $a Moretta, Lorenzo $u Istituto Giannina Gaslini, Genova, Italy.
- 700 1_
- $a Odunsi, Adekunke $u Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA.
- 700 1_
- $a Okada, Hideho $u Dept. of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
- 700 1_
- $a Palucka, Anna Karolina $u The Jackson Laboratory for Genomics Medicine, Farmington, CT, USA.
- 700 1_
- $a Peter, Marcus E $u Div. of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
- 700 1_
- $a Pienta, Kenneth J $u The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
- 700 1_
- $a Porgador, Angel $u The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- 700 1_
- $a Prendergast, George C $u Lankenau Institute for Medical Research, Wynnewood, PA, USA. Dept. of Pathology, Anatomy and Cell Biology, Sidney Kimmel Medical College, Philadelphia, PA, USA. Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
- 700 1_
- $a Rabinovich, Gabriel A $u Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina.
- 700 1_
- $a Restifo, Nicholas P $u National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
- 700 1_
- $a Rizvi, Naiyer $u Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.
- 700 1_
- $a Sautès-Fridman, Catherine $u INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Université Pierre et Marie Curie/Paris VI, Paris, France. Equipe 13, Centre de Recherche des Cordeliers, Paris, France.
- 700 1_
- $a Schreiber, Hans $u Dept. of Pathology, The Cancer Research Center, The University of Chicago, Chicago, IL, USA.
- 700 1_
- $a Seliger, Barbara $u Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
- 700 1_
- $a Shiku, Hiroshi $u Dept. of Immuno-GeneTherapy, Mie University Graduate School of Medicine, Tsu, Japan.
- 700 1_
- $a Silva-Santos, Bruno $u Instituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal.
- 700 1_
- $a Smyth, Mark J $u Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia.
- 700 1_
- $a Speiser, Daniel E $u Dept. of Oncology, University of Lausanne, Lausanne, Switzerland. Ludwig Cancer Research Center, Lausanne, Switzerland.
- 700 1_
- $a Spisek, Radek $u Sotio a.c., Prague, Czech Republic. Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
- 700 1_
- $a Srivastava, Pramod K $u Dept. of Immunology, University of Connecticut School of Medicine, Farmington, CT, USA. Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA.
- 700 1_
- $a Talmadge, James E $u Laboratory of Transplantation Immunology, Dept. of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
- 700 1_
- $a Tartour, Eric $u Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. INSERM, U970, Paris, France. Paris-Cardiovascular Research Center (PARCC), Paris, France. Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France.
- 700 1_
- $a Van Der Burg, Sjoerd H $u Dept. of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Van Den Eynde, Benoît J $u Ludwig Institute for Cancer Research, Brussels, Belgium. de Duve Institute, Brussels, Belgium. Université Catholique de Louvain, Brussels, Belgium.
- 700 1_
- $a Vile, Richard $u Dept. of Molecular Medicine and Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
- 700 1_
- $a Wagner, Hermann $u Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Munich, Germany.
- 700 1_
- $a Weber, Jeffrey S $u Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, FL, USA.
- 700 1_
- $a Whiteside, Theresa L $u University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- 700 1_
- $a Wolchok, Jedd D $u Dept. of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA. Weill Cornell Medical College, New York, NY, USA.
- 700 1_
- $a Zitvogel, Laurence $u Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1015, Villejuif, France. Centre d'Investigation Clinique Biothérapie 507 (CICBT507), Gustave Roussy Cancer Campus, Villejuif, France.
- 700 1_
- $a Zou, Weiping $u University of Michigan, School of Medicine, Ann Arbor, MI, USA.
- 700 1_
- $a Kroemer, Guido $u Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France.
- 773 0_
- $w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 5, č. 24 (2014), s. 12472-508
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25537519 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160804085903 $b ABA008
- 999 __
- $a ok $b bmc $g 1102709 $s 924634
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 5 $c 24 $d 12472-508 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
- LZP __
- $a Pubmed-20160108
